bi 44370
Small moleculeexperimental
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2007 (NCT02215018)
Timeline
Indications
Mechanism of action
- Calcitonin gene-related peptide 1INHIBITOR
CALCA inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bi 44370
- bi 44370
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02215759 | Phase 1 | Jan 1, 2009 | Boehringer Ingelheim |
| NCT00743015 | Phase 1 | Sep 1, 2008 | Boehringer Ingelheim |
| NCT02215031 | Phase 1 | Sep 1, 2008 | Boehringer Ingelheim |
| NCT02215772 | Phase 1 | Sep 1, 2008 | Boehringer Ingelheim |
| NCT00751803 | Phase 2 | Aug 1, 2008 | Boehringer Ingelheim |
| NCT02217514 | Phase 1 | Feb 1, 2008 | Boehringer Ingelheim |
| NCT02215746 | Phase 1 | Jan 1, 2008 | Boehringer Ingelheim |
| NCT02215018 | Phase 1 | Apr 1, 2007 | Boehringer Ingelheim |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 8 | 8 | 2 | 2007 |
1 organizations
Page 1 / 1